Anders Vikström

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Fabrice Barlési, Arnaud Scherpereel, Achim Rittmeyer et al. · Journal of Clinical Oncology · 2013 · 326 citations

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Fabrice Barlési, Arnaud Scherpereel, R. Gervais et al. · Annals of Oncology · 2014 · 169 citations · Full text

Oncology, First-line Cisplatin–pemetrexed–bevacizumab, Phase Iii Trial +8

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 123 citations · Full text

Analysis of breath samples for lung cancer survival

Birgitta Schmekel, Fredrik Winquist, Anders Vikström · Analytica Chimica Acta · 2014 · 44 citations

Breath Samples, Lung Deposition, Medicine +5

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study

Gunnar Hillerdal, Jens Benn Sørensen, Stein Sundstrøm et al. · Journal of Thoracic Oncology · 2008 · 44 citations

Malignant Pleural Mesothelioma, Medicine, Pathology +7